{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000174","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.770898+00:00","generated_at":"2026-05-16T10:59:33.830387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR","bullets":["Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).","Diluted EPS $2.55-$2.65 (higher end); free cash flow $1.6-$1.9B (higher end).","Duvakitug milestones expected to add $500M revenue and ~$400-430M adjusted EBITDA.","2027 targets: low-single-digit revenue growth, 30% operating margin, FCF >$2.7B, net leverage <2x.","2030 targets: mid-single-digit CAGR, >30% operating margin, FCF >$3.5B, cumulative savings $700M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000174","json":"https://secwatch.observer/filing/0001171843-26-000174.json","markdown":"https://secwatch.observer/filing/0001171843-26-000174.md","text":"https://secwatch.observer/filing/0001171843-26-000174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184326000174/0001171843-26-000174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184326000174/f8k_011126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:33.830387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}